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Background/introduction
Symptomatic localized adenomyosis is generally treated
conservatively, or with more radical treatments such as
hysterectomy. An effective non-invasive therapy is needed,
especially for those who wish to preserve their fertility.
MR-guided Focused Ultrasound ablation (MRgFUS) has
been shown as an effective treatment for symptomatic
uterine leiomyomas with a large non-perfused volume
(NPV) immediately after treatment. Our specific aim was
to compare the change in NPV in subjects with localized
adenomyomas treated with MRgFUS, with the change in
NPV in subjects treated with MRgFUS for symptomatic
uterine leiomyomas to determine if similar results were
achieved in the localized adenomyoma cohort.
Methods
With IRB approval, we performed a HIPAA compliant
retrospective review of women treated with MRgFUS at
our comprehensive treatment center for symptomatic
localized adenomyosis. We matched cases with leio-
myoma bearing-controls with the following criteria:
1) Similar baseline total lesion volume. 2) Similar number
of lesions at baseline. 3) Similar age. Subjects who had
imaging performed both prior and immediately post-
treatment were included. All lesions were contoured on
the T1 post-contrast sagittal series, and volumes were
calculated with a validated proprietary software. All con-
tours were confirmed by two genitourinatry trained radi-
ologists. The software automatically calculated the total
lesion volume and its perfused volume, from which we
derived the NPV by subtracting the perfused lesion
volume from the total lesion volume.
Results and conclusions
10 lesions in 9 subjects were analyzed. Adenomyoma
and leiomyoma cohorts were similar in baseline charac-
teristics including age (42 vs. 43) and mean baseline
total lesion volume (96cc vs. 97cc), respectively. Post-tx
characteristics were also similar between adenomyoma
and leiomyoma cohorts in mean total lesion volume
(97cc vs. 90 cc), mean post-tx NPV (41cc vs. 52cc) and
sonication number (74 vs. 65), respectively.
From our results we can conclude that MRgFUS can
offer significant reduction in perfused volume of localized
adenomyosis similar to leiomyoma, and may offer com-
plete ablation of the adenomyoma. Therefore indicating
MRgFUS may be a viable non-invasive treatment for
patients with symptomatic adenomyosis, and may offer an
alternative to conventional therapies.
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